Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre

Tarricone, Ilaria; Casoria, Michela; Gozzi, Beatrice Ferrari; Grieco, Daniela; Menchetti, Marco; Serretti, Alessandro; Ujkaj, Manjola; Pastorelli, Francesca; Berardi, Domenico
January 2006
BMC Psychiatry;2006, Vol. 6, p11
Academic Journal
Background: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non-treated control patients. Methods: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels. Results: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs. Conclusion: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.


Related Articles

  • Possible Link Explored Between Antipsychotics And Several Conditions.  // RN;Jun2004, Vol. 67 Issue 6, p76 

    Explores the possible link between antipsychotics and several conditions. Recommendation for monitoring closely on patients who take antipsychotics for signs that they are developing diabetes, obesity, or high cholesterol; Emergence of the consensus statement made by the American Diabetes...

  • The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Fell, M. J.; Anjum, N.; Dickinson, K.; Marshall, K. M.; Peltola, L. M.; Vickers, S.; Cheetham, S.; Neill, J. C. // Psychopharmacology;Oct2007, Vol. 194 Issue 2, p221 

    Treatment with some antipsychotic drugs may result in excessive body weight gain which can have detrimental effects on patient compliance, morbidity and mortality. The aim of the present study was to investigate the effect of atypical antipsychotic drugs on dietary macronutrient selection, body...

  • Prevalence of Obesity in Patients Receiving Depot Antipsychotics. Silverstone, T.; Smith, G.; Goodall, E. // British Journal of Psychiatry;Aug88, Vol. 153, p214 

    Antipsychotic drugs have long been noted to cause pronounced weight gain, and drug-induced obesity can assume major clinical importance in long-term medication in the management of chronic schizophrenia. Obesity is associated with increased morbidity and may reduce compliance, leading to a...

  • The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Mulder, H.; Franke, B.; Beek van der, A. Aart Van der; Arends, J.; Wilmink, F. W.; Egberts, A. C. G.; Scheffer, H. // Pharmacogenomics Journal;2007, Vol. 7 Issue 5, p318 

    The use of antipsychotics is associated with an increased risk of obesity. This consideration makes it important to search for determinants that can predict the risk for antipsychotic-induced obesity. In this cross-sectional study, we investigated whether polymorphisms in the HTR2C gene were...

  • Yeni KuÅŸak Antipsikotiklerin Metabolik Yan Etkileri. Mete, Levent; Ünsal, Pinar Çetinay // Klinik Psikofarmakoloji Bulteni;Sep2004, Vol. 14 Issue 3, p168 

    With the introduction of atypical antipsychotics, a promising new era in the treatment of schizophrenia and psychotic disorders has begun. These drugs effect a broader range of schizophrenic psychopathology by improving depressive symptomatology and cognitive functions. These drugs are also...

  • Age a factor in antipsychotic-associated diabetes.  // Reactions Weekly;9/13/2008, Issue 1219, p4 

    The article discusses research being done on the association of typical and atypical antipsychotics with diabetes mellitus (DM). It references a study by A. Hammerman et al., published in the "Annals of Pharmacotherapy" in 2008. The researchers found that both atypical and atypical...

  • Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. Gunasekara, N.S.; Spencer, C.M.; Keating, G.M.; Gunasekara, Nishan S; Spencer, Caroline M; Keating, Gillian M // CNS Drugs;2002, Vol. 16 Issue 9, p645 

    Unlabelled: Ziprasidone is a novel antipsychotic agent with a pharmacological profile distinct from that of other currently available novel or classical antipsychotics. In preclinical studies, ziprasidone was predicted to have efficacy against positive, negative and affective...

  • New study designs for new antipsychotics. Kahn, S. // Psychopharmacology;2002, Vol. 162 Issue 1, p92 

    Focuses on study designs for new antipsychotics. Problems in comparing new with older antipsychotics; Questions which need to be addressed in assessing the new antipsychotics.

  • Expert consensus-based medication-use evaluation criteria for atypical antipsychotic drugs. Love, Raymond C.; Mackowick, Marie; Carpenter, Daniel; Burks, Emalie J. // American Journal of Health-System Pharmacy;12/1/2003, Vol. 60 Issue 23, p2455 

    Focuses on medication-use criteria developed for the appropriate use of atypical antipsychotics through a national consensus process utilizing an expert panel. Demonstration of the utility of a consensus-based process in addressing issues and practices not adequately addressed in the scientific...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics